Allianz Asset Management GmbH Takes Position in LivaNova PLC (NASDAQ:LIVN)

Key Points

• Allianz Asset Management GmbH has invested approximately $593,000 in LivaNova PLC, acquiring 15,100 shares in the first quarter of the year.
• Several other hedge funds have also increased their holdings in LivaNova, with notable purchases including one by Foundry Partners LLC valued at about $3.8 million.
• LivaNova's stock has seen mixed analyst ratings, with target prices ranging from $55.00 to $64.00, and an average rating of "Buy".

Allianz Asset Management GmbH acquired a new position in LivaNova PLC (NASDAQ:LIVN - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 15,100 shares of the company's stock, valued at approximately $593,000.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Foundry Partners LLC acquired a new stake in shares of LivaNova in the first quarter worth $3,816,000. CWM LLC grew its stake in shares of LivaNova by 52.3% in the first quarter. CWM LLC now owns 871 shares of the company's stock worth $34,000 after acquiring an additional 299 shares during the last quarter. New York State Common Retirement Fund lifted its position in LivaNova by 28.6% in the first quarter. New York State Common Retirement Fund now owns 48,290 shares of the company's stock worth $1,897,000 after purchasing an additional 10,733 shares during the period. DekaBank Deutsche Girozentrale lifted its position in LivaNova by 2.4% in the first quarter. DekaBank Deutsche Girozentrale now owns 21,000 shares of the company's stock worth $817,000 after purchasing an additional 500 shares during the period. Finally, Envestnet Asset Management Inc. lifted its position in LivaNova by 6.6% in the first quarter. Envestnet Asset Management Inc. now owns 46,833 shares of the company's stock worth $1,840,000 after purchasing an additional 2,901 shares during the period. Institutional investors and hedge funds own 97.64% of the company's stock.

Analyst Ratings Changes

Several research analysts recently commented on the company. Barclays reduced their target price on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a research report on Thursday, May 8th. Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 target price on shares of LivaNova in a research report on Tuesday, May 13th. Wall Street Zen cut LivaNova from a "strong-buy" rating to a "buy" rating in a research report on Thursday, May 8th. Wolfe Research raised LivaNova from a "peer perform" rating to an "outperform" rating and set a $60.00 target price for the company in a research report on Tuesday, May 20th. Finally, Robert W. Baird lifted their price objective on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, LivaNova currently has an average rating of "Buy" and an average price target of $59.29.

LivaNova Price Performance

Shares of NASDAQ:LIVN traded down $0.15 during midday trading on Tuesday, reaching $42.61. The company's stock had a trading volume of 1,362,346 shares, compared to its average volume of 702,557. LivaNova PLC has a fifty-two week low of $32.48 and a fifty-two week high of $57.35. The company has a market capitalization of $2.32 billion, a P/E ratio of -10.42 and a beta of 0.92. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.58 and a quick ratio of 1.37. The business's fifty day simple moving average is $44.65 and its 200-day simple moving average is $42.79.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.